nasuspharma.com (NSRX) - Market Cap to Net Income

Nasus Pharma Ltd. - graphic logo of issuer NSRX

Current price action for Nasus Pharma Ltd (NSRX) demonstrates the -10.00 indicator. Nasus Pharma Ltd generates revenue through the sale of nasal allergy and antiviral treatments via the public sector and pharmacies, targeting healthcare professionals and travelers. The business is implementing ESG standards by reducing chemical waste during the production of powder-based medications. However, a narrow product portfolio and strict regulatory oversight create risks for scaling and the stability of raw material supplies.

nasuspharma.com (NSRX): Price to Earnings Ratio from 08/14/2025 to 11/16/2026

Analytical breakdowns for Nasus Pharma Ltd

Summary company analysis:NSRX, Nasus Pharma Ltd.
Signature product of nasuspharma.com

The margin of safety assessment for Nasus Pharma Ltd (NSRX) is based on the P/E ratio, which relates the market value of the business to its net income, allowing investors to determine the extent of the asset's overvaluation. By analyzing the company's historical P/E range with a value of -10.00, one can evaluate the capitalization efficiency of the intellectual capital of intranasal drug delivery experts and their ability to convert academic freedom into tangible financial results.